Second generation CAR T-cell therapy trialled in patients

A new CAR T-cell therapy developed by scientists at UCL has fewer ‘toxic’ side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase I clinical trial of patients at University College London Hospitals (UCLH).

Researchers say the findings offer new hope to adult patients with ‘relapsed B-cell acute lymphoblastic leukaemia’ (r/r B-ALL), for which there is currently no approved ‘curative’ treatment available.

Read the full update at UCL News.